SCYX Scynexis Inc
Price (delayed)
$0.9424
Market cap
$36.74M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.44
Enterprise value
$36.41M
SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Its lead candidate, ibrexafungerp (formerly
Highlights
Scynexis's gross margin has increased by 12% YoY
The gross profit has soared by 161% QoQ but it has shrunk by 97% YoY
The company's net income has shrunk by 132% YoY but it rose by 42% QoQ
Scynexis's revenue has shrunk by 97% YoY and by 56% QoQ
Scynexis's quick ratio has shrunk by 51% YoY and by 5% QoQ
Key stats
What are the main financial stats of SCYX
Market
Valuations
Earnings
Shares outstanding
38.98M
Market cap
$36.74M
Enterprise value
$36.41M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.65
Price to sales (P/S)
12.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.72
Revenue
$3.75M
Gross profit
$3.75M
Operating income
-$37.12M
Net income
-$21.29M
EBIT
-$20.31M
EBITDA
-$20.31M
Free cash flow
-$24.01M
Per share
Balance sheet
Liquidity
EPS
-$0.44
EPS diluted
-$0.44
Free cash flow per share
-$0.49
Book value per share
$1.45
Revenue per share
$0.08
TBVPS
$1.87
Total assets
$90.64M
Total liabilities
$35.57M
Debt
$16.27M
Equity
$55.08M
Working capital
$48.08M
Debt to equity
0.3
Current ratio
3
Quick ratio
2.91
Net debt/EBITDA
0.02
Margins
Efficiency
Dividend
EBITDA margin
-542.2%
Gross margin
100%
Net margin
-568.3%
Operating margin
-990.8%
Return on assets
-20.5%
Return on equity
-34.3%
Return on invested capital
-30.3%
Return on capital employed
-30.5%
Return on sales
-542.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SCYX stock price
How has the Scynexis stock price performed over time
Intraday
-1.02%
1 week
-8.5%
1 month
-8.5%
1 year
-36.75%
YTD
-22.12%
QTD
-1.02%
Financial performance
How have Scynexis's revenue and profit performed over time
Revenue
$3.75M
Gross profit
$3.75M
Operating income
-$37.12M
Net income
-$21.29M
Gross margin
100%
Net margin
-568.3%
The gross profit has soared by 161% QoQ but it has shrunk by 97% YoY
SCYX's operating income has shrunk by 151% YoY but it is up by 29% QoQ
The company's net income has shrunk by 132% YoY but it rose by 42% QoQ
Scynexis's revenue has shrunk by 97% YoY and by 56% QoQ
Growth
What is Scynexis's growth rate over time
Valuation
What is Scynexis stock price valuation
P/E
N/A
P/B
0.65
P/S
12.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.72
The company's EPS has shrunk by 131% YoY but it rose by 42% QoQ
SCYX's price to book (P/B) is 83% lower than its 5-year quarterly average of 3.9 and 28% lower than its last 4 quarters average of 0.9
The equity has declined by 25% year-on-year and by 6% since the previous quarter
Scynexis's revenue has shrunk by 97% YoY and by 56% QoQ
The P/S is 40% higher than the last 4 quarters average of 8.7 but 24% lower than the 5-year quarterly average of 16.0
Efficiency
How efficient is Scynexis business performance
Scynexis's return on assets has shrunk by 138% YoY but it has increased by 36% QoQ
SCYX's return on invested capital has dropped by 136% year-on-year but it is up by 37% since the previous quarter
The return on equity has dropped by 129% year-on-year but it has increased by 37% since the previous quarter
The company's return on sales fell by 31% QoQ
Dividends
What is SCYX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SCYX.
Financial health
How did Scynexis financials performed over time
The total assets is 155% more than the total liabilities
The current ratio has plunged by 52% YoY and by 4.2% from the previous quarter
Scynexis's quick ratio has shrunk by 51% YoY and by 5% QoQ
Scynexis's debt is 70% less than its equity
The company's debt to equity rose by 43% YoY and by 11% QoQ
The equity has declined by 25% year-on-year and by 6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.